Intervention Review

You have free access to this content

Atovaquone-proguanil for treating uncomplicated malaria

  1. Alex Osei-Akoto1,*,
  2. Lois C Orton2,
  3. Shirley Owusu-Ofori3

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 26 JUN 2005

DOI: 10.1002/14651858.CD004529.pub2

Database Title

Additional Information

How to Cite

Osei-Akoto A, Orton LC, Owusu-Ofori S. Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD004529. DOI: 10.1002/14651858.CD004529.pub2.

Author Information

  1. 1

    Komfo Anokye Teaching Hospital, Department of Child Health, Kumasi, Ghana

  2. 2

    University of Manchester, School of Nursing, Midwifery and Social Work, Manchester, UK

  3. 3

    Komfo Anokye Teaching Hospital, Department of Medicine, Kumasi, Ghana

*Alex Osei-Akoto, Department of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana. oseiyakoto@hotmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (58K)Standard (317K)Full (560K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Atovaquone-proguanil (AP) versus chloroquine, Outcome 1 Treatment failure on or by day 28.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Atovaquone-proguanil (AP) versus chloroquine, Outcome 2 Parasite clearance time (mean; h).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Atovaquone-proguanil (AP) versus chloroquine, Outcome 3 Fever clearance time (mean; h).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Atovaquone-proguanil (AP) versus chloroquine, Outcome 4 Adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Atovaquone-proguanil (AP) versus amodiaquine, Outcome 1 Treatment failure on or by day 28.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Atovaquone-proguanil (AP) versus amodiaquine, Outcome 2 Treatment failure on or by day 14.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Atovaquone-proguanil (AP) versus amodiaquine, Outcome 3 Parasite clearance time (mean; h).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Atovaquone-proguanil (AP) versus amodiaquine, Outcome 4 Fever clearance time (mean; h).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Atovaquone-proguanil (AP) versus amodiaquine, Outcome 5 Adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Atovaquone-proguanil (AP) versus sulfadoxine-pyrimethamine (SP), Outcome 1 Treatment failure on or by day 28.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Atovaquone-proguanil (AP) versus sulfadoxine-pyrimethamine (SP), Outcome 2 Parasite clearance time (mean; h).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Atovaquone-proguanil (AP) versus sulfadoxine-pyrimethamine (SP), Outcome 3 Fever clearance time (mean; h).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Atovaquone-proguanil (AP) versus sulfadoxine-pyrimethamine (SP), Outcome 4 Progression to severe disease.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Atovaquone-proguanil (AP) versus sulfadoxine-pyrimethamine (SP), Outcome 5 Adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Atovaquone-proguanil (AP) versus quinine plus tetracycline (Q plus T), Outcome 1 Treatment failure on or by day 28.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Atovaquone-proguanil (AP) versus quinine plus tetracycline (Q plus T), Outcome 2 Parasite clearance time (mean; h).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Atovaquone-proguanil (AP) versus quinine plus tetracycline (Q plus T), Outcome 3 Fever clearance time (mean; h).
[Analysis 4.4]
Analysis 4.4. Comparison 4 Atovaquone-proguanil (AP) versus quinine plus tetracycline (Q plus T), Outcome 4 Adverse events.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Atovaquone-proguanil (AP) versus halofantrine, Outcome 1 Treatment failure on or by day 28.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Atovaquone-proguanil (AP) versus halofantrine, Outcome 2 Parasite clearance time (mean; h).
[Analysis 5.3]
Analysis 5.3. Comparison 5 Atovaquone-proguanil (AP) versus halofantrine, Outcome 3 Fever clearance time (mean; h).
[Analysis 5.4]
Analysis 5.4. Comparison 5 Atovaquone-proguanil (AP) versus halofantrine, Outcome 4 Adverse events.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Atovaquone-proguanil (AP) versus mefloquine, Outcome 1 Treatment failure on or by day 28.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Atovaquone-proguanil (AP) versus mefloquine, Outcome 2 Parasite clearance time (mean; h).
[Analysis 6.3]
Analysis 6.3. Comparison 6 Atovaquone-proguanil (AP) versus mefloquine, Outcome 3 Fever clearance time (mean; h).
[Analysis 6.4]
Analysis 6.4. Comparison 6 Atovaquone-proguanil (AP) versus mefloquine, Outcome 4 Adverse events.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Atovaquone-proguanil (AP) versus artesunate plus mefloquine (AS plus MQ), Outcome 1 Treatment failure on or by day 14.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Atovaquone-proguanil (AP) versus artesunate plus mefloquine (AS plus MQ), Outcome 2 Treatment failure on or by day 28 adjusted by PCR.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Atovaquone-proguanil (AP) versus artesunate plus mefloquine (AS plus MQ), Outcome 3 Adverse events.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Atovaquone-proguanil (AP) versus dihydroartemisinin, piperaquine, trimethoprim, and primaquine (CV8), Outcome 1 Treatment failure on or by day 28.
[Analysis 8.2]
Analysis 8.2. Comparison 8 Atovaquone-proguanil (AP) versus dihydroartemisinin, piperaquine, trimethoprim, and primaquine (CV8), Outcome 2 Parasite clearance time (mean; h).
[Analysis 8.3]
Analysis 8.3. Comparison 8 Atovaquone-proguanil (AP) versus dihydroartemisinin, piperaquine, trimethoprim, and primaquine (CV8), Outcome 3 Fever clearance time (mean; h).
[Analysis 8.4]
Analysis 8.4. Comparison 8 Atovaquone-proguanil (AP) versus dihydroartemisinin, piperaquine, trimethoprim, and primaquine (CV8), Outcome 4 Adverse events.
View Full Article (HTML) Summary (58K)Standard (317K)Full (560K)